Comparative Pharmacology
Head-to-head clinical analysis: NYDRAZID versus SODIUM AMINOSALICYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYDRAZID versus SODIUM AMINOSALICYLATE.
NYDRAZID vs SODIUM AMINOSALICYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.
Sodium aminosalicylate inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking bacterial growth.
300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.
4 g orally three times daily (total daily dose 12 g) for tuberculosis treatment. Also available as 10 g in 250 mL for intravenous infusion over 5-6 hours, typically once daily.
None Documented
None Documented
Terminal elimination half-life: 1-4 hours (fast acetylators), 2-8 hours (slow acetylators). Half-life prolonged in hepatic impairment; adjust dose.
0.75-1.5 hours (parent drug); prolongs to 4-6 hours in renal impairment or with probenecid coadministration. Rapid acetylation phenotype reduces half-life by ~30%.
Renal excretion of unchanged drug and metabolites; 50-70% excreted in urine within 24 hours, mainly as acetylisoniazid and isonicotinic acid. Biliary/fecal: <10%.
Renal: >80% as metabolites (acetylated and free), with 50-60% as N-acetyl-4-aminosalicylic acid; biliary/fecal: <1%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent